

Algorithm, Clinical Highlights, Annotations

Reordered algorithm #'s 2 – 5 on Diagnostic Testing for Diabetes Algorithm.

Definitions:

Updated definitions of prediabetes and type 2 diabetes mellitus.

Annotations:

- *1) Updated A1c diagnostic guideline limits.
- *2) Updated A1c diagnostic guideline limits.
- *4) Updated parameters of diagnosis of type 2 diabetes.
- *7) Updated references and added statement on hypoglycemia protocol in Inpatient Diabetes Management section.
- 9) Moved insulin initiating information to Annotation #20 – Prescribe Insulin Therapy.
- 10) Moved physical activity and weight loss verbiage from supplements section to weight management section.
Revised weight management section.
- *11) Added section on conclusion of 2009 meta-analysis that analyzed the five controlled trials (ACCORD, ADVANCE, VADT, PROactive and UKPDS trials) for effects of intensive glucose control on cardiovascular outcomes.
- *13) Updated language on combination therapy with statins and other lipid drugs to the LDL less than 100mg/dL section.
Updated aspirin section.
- 14) Removed language from LDL less than 70mg/dL section and referred reader to Annotation #13, as well as the ICSI Lipid Management in Adults and Stable Coronary Artery Disease guidelines.
- 16) Added section on evaluation of obstructive sleep apnea.
Added section on ophthalmology/optometry examination.
- *18) Revised glycemic control section. Pharmacologic agents and strategies for glycemic control verbiage moved to Annotation #19.
- 19) Added glycemic control verbiage from Annotation #18.
- *20) Insulin initiating information moved from Annotation #9 to this section.
Added data from NEJM article on a 3-year randomized trial to study the efficacy of three different insulin regimens; NEJM, 2009, Holman, et al.
Updated the Insulin Preparations table.
Updated cost indicators.
Added statement on U-500.
- *22) Drug Tables:
Added Saxagliptin to Dipeptidyl Peptidase-4 (DPP-4) Inhibitor table.
Updated Sitagliptin information to include pancreatitis warning.
Added Liraglutide injection to Glucagon Like Peptide-1 table.
Added new Bile Acid Sequestrant table to include colesevalam.

- Added new Bromocriptine Meslate table.
Included additional metformin information to combination products table.
- *27) Added language to reflect the conclusions of the ACCORD, UKPDS, HOT and ADVANCE trials.
Revised blood pressure systolic target from 130 mmHg to 140 mmHg.
Revised blood pressure diastolic target from 80 mmHg to 85 mmHg.
Added table to compare goal versus mean achieved blood pressure levels in randomized trials (ACCORD, UKPDS, HOT and ADVANCE).
 - *28) Updated thiazide information to include INVEST study data (first line therapy).
 - *34) Changed monitoring of fasting lipid profile yearly to monitoring low density lipoprotein or fasting lipid profile yearly.
Added eye exam and foot exam.
 - *35) Added fundus photography language to dilated eye exam.
Added PHQ-9 depression assessment to cardiovascular and cerebrovascular complication assessment.
 - 36) Removed thiazide diuretics language.

Appendices:

Added Appendix C for information on how to perform a tuning fork exam.

Priority Aims & Suggested Measures, Measurement Specifications

Modified aims and measures section to reflect that measures are diabetes specific.

Removed measures related to smoking and aspirin.

Revised measures to include new blood pressure measurement of 140/85 mmHg.

Resources Available

Updated table.

General Guideline Revisions

Guideline updated to include revised blood pressure target of 140 mmHg systolic and 85 mmHg diastolic.

Guideline updated with 2010 Diabetes Standards of Care reference.

**An asterisk indicates any changes in clinical practice recommendations*